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Background: Participants in clinical research studies often do not reflect the populations for which healthcare
interventions are needed or will be used. Enhancing representation of under-served groups in clinical research is
important to ensure that research findings are widely applicable. We describe a multicomponent workstream
project to improve representation of under-served groups in clinical trials.
Methods: The project comprised three main strands: (1) a targeted scoping review of literature to identify previous
work characterising under-served groups and barriers to inclusion, (2) surveys of professional stakeholders and
participant representative groups involved in research delivery to refine these initial findings and identify examples
of innovation and good practice and (3) a series of workshops bringing together key stakeholders from funding,
design, delivery and participant groups to reach consensus on definitions, barriers and a strategic roadmap for
future work. The work was commissioned by the UK National Institute for Health Research Clinical Research
Network. Output from these strands was integrated by a steering committee to generate a series of goals,
workstream plans and a strategic roadmap for future development work in this area.
Results: ‘Under-served groups’ was identified and agreed by the stakeholder group as the preferred term. Three-
quarters of stakeholders felt that a clear definition of under-served groups did not currently exist; definition was
challenging and context-specific, but exemplar groups (e.g. those with language barriers or mental illness) were
identified as under-served. Barriers to successful inclusion of under-served groups could be clustered into
communication between research teams and participant groups; how trials are designed and delivered, differing
agendas of research teams and participant groups; and lack of trust in the research process. Four key goals for
future work were identified: building long-term relationships with under-served groups, developing training
resources to improve design and delivery of trials for under-served groups, developing infrastructure and systems to
support this work and working with funders, regulators and other stakeholders to remove barriers to inclusion.
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Conclusions: The work of the INCLUDE group over the next 12 months will build on these findings by generating
resources customised for different under-served groups to improve the representativeness of trial populations.
Keywords: Trials, Roadmap, Under-served, Recruitment, StakeholderIntroduction
Evidence from randomised controlled trials constitutes
the most rigorous test of efficacy, effectiveness and safety
for healthcare interventions. Such evidence is essential
to identify both what works and what does not work,
and underpins the highest grade of recommendations in
guidelines that shape clinical practice [1]. However, pop-
ulations recruited into trials are often not representative
of the target population who require evidence about
interventions. For example, participants in heart failure
trials are on average 20 years younger than those seen in
clinical practice; patients in cancer trials lack the comor-
bidity commonly seen in clinical practice; and patients
in diabetes trials are not the ethnically diverse popula-
tions typically seen in clinical practice [2–4]. The conse-
quence of this disconnect between trial populations and
the real world are manifold—treatment benefits and
harms seen in trials may not translate to those seen in
clinical practice [5], and important findings specific to
different populations may be missed. Trial interventions
may not be deliverable to, or may not benefit, all groups
within a population and only by including a range of
groups can researchers, patients, clinicians and policy-
makers know that results are applicable to all within a
population. Whilst including under-served groups may
require more time, money and effort, the value of the
results is likely to be higher. Finally, this lack of repre-
sentation could be interpreted as discriminatory against
some groups.
Some reasons for this disconnect between research
and practice have been previously described. Trials often
seek a narrowly defined, homogenous population to re-
duce variance and hence sample size, and the imposition
of stringent inclusion and exclusion criteria leads to un-
representative trial populations [2, 6, 7]. Recruitment
strategies and trial logistics may also act as barriers to
entry and retention. Examples include recruiting via
tertiary care centres, or in urban environments far from
rural populations, failing to provide taxi transportation
for people who have poor mobility, or failing to provide
translated study information for those who cannot read
a given language [8]. Pressure from funders to recruit
rapidly may also favour approaching groups who are
easy to recruit, rather than recruiting a more representa-
tive, but harder to recruit, range of participants.
At present, a systematic approach to understanding
and overcoming the lack of representativeness of trialpopulations has not been attempted. In the UK, the
National Institute for Health Research (NIHR), a major
funder of clinical trials designed to underpin guidelines
and clinical practice, identified the need for a work-
stream to address this issue, latterly named the ‘Innova-
tions in Clinical Trial Design and Delivery for the
Under-served’ (INCLUDE) project. This paper reports
the results of the first phase of this work which had the
following key objectives: to create a framework to allow
the identification of groups who are historically under-
represented in trials, to identify barriers and drivers to
inclusion and to facilitate innovations in trial design and
delivery to improve inclusion of under-represented groups.
Methods
A series of tasks and events together addressed the
objectives of the programme, which we describe below
(summarised in Fig. 1).
Steering group and stakeholder group meetings
Three stakeholder group meetings were held—in March
2018 as a project initiation workshop, December 2018 as
a prioritisation and definition consensus meeting and
June 2019 as a goal and future work consensus meeting.
Stakeholder groups relevant to the process were mapped
by the project steering group; representatives were
selected through organisational structures and by recom-
mendation from within each stakeholder organisation.
Stakeholders invited to these meetings included NIHR
national speciality leads and members from the NIHR
Clinical Research Network, public and patient groups
and charities, practitioners and healthcare professionals,
the life sciences industry, funders and regulatory bodies.
Additional meetings of a smaller steering group, com-
prising NIHR project and research network staff, clinical
academics, trialists and leaders of public engagement
activities, were held between these meetings to interpret
and refine findings, provide strategic direction to the
project, and to plan the content of the stakeholder group
meetings.
Literature review
A targeted scoping review of published literature was
undertaken by the NIHR Innovation Observatory relat-
ing to the concept of under-representation as it appears
within clinical trial design and/or delivery. Keywords
identified by the study team included under-represented
Fig. 1 Components of the programme. SG steering group
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medical settings, barriers to participation and patient
participation. A combination keyword method for the
identification and inclusion of relevant studies was
employed, including searches undertaken in MEDLINE,
Embase, Cochrane Database of Systematic Reviews,
Database of Promoting Health Effectiveness Reviews
(DoPHER), Trial Register of Promoting Health Interven-
tions (TRoPHI), Scopus, Cumulative Index to Nursing
and Allied Health Literature (CINAHL) and PsycINFO.
Searches were conducted in April and May 2018 and
were limited to a 5-year timeframe, starting 1 March
2013. Results not in English were excluded, as were re-
sults describing under-representation of an intervention
as opposed to a group of participants. Letters, commen-
taries, editorials and animal studies were also excluded.
A sample search strategy is shown in Additional file 1.
Retrieved references were deduplicated in EndNote
before scrutiny by the research team for relevance. All
titles were scrutinised; clearly irrelevant titles were
removed, and the remaining candidate studies proceeded
to abstract review, where irrelevant abstracts were fur-
ther removed. Much of the available literature focussed
on patients with cancer; thus, studies were divided into
those focussing on cancer and non-cancer populations.
Key findings were extracted by a research team member
(SP) before further grouping into themes by the steering
group. Final results were then fed into the work of the
stakeholder meetings.
Surveys
Two surveys were designed, asking very similar ques-
tions to two distinct target groups. The first groupconstituted stakeholders identified from potentially
under-represented groups. Stakeholders were mapped by
the steering group with additional suggestions from the
wider stakeholder group. The survey was sent to charity
users, public and patient group representatives, NIHR
Clinical Research Network research ambassadors and
Newcastle University VOICE (Valuing Our Intellectual
Capital and Experience, a public engagement organisa-
tion) members. The second group constituted profes-
sional stakeholders, drawn from a range of clinical
research leaders within the NIHR Clinical Research Net-
works, charities, clinical trial units, other parts of the
NIHR organisation, industry, NHS and universities. As
with the professional group, recipients were identified by
the steering group and wider stakeholder group, with
organisations suggesting additional contacts within their
organisations. Surveys were hosted on SurveyMonkey
and links sent via targeted emails. Results from the
surveys were analysed by thematic analysis of free-text
responses. The survey questionnaires are presented in
Additional file 2.
Results
Initial stakeholder meeting
At the initial stakeholder meeting, held in March 2018,
17/23 (74%) of participants answered ‘no’ to the state-
ment: “Do you feel that there is a sufficiently consistent
definition of what is meant by ‘under-represented groups’
in clinical trials across stakeholders?”. No stakeholder at
the meeting agreed with the statement, and 6/23 (26%)
held no opinion. Stakeholders provided examples of
under-represented groups (for example older people,
pregnant women, people from traveller communities,
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communities), innovative practice aimed at successfully
engaging with and recruiting such groups (for example
using researchers from within the communities, long-term
engagement and co-design of studies by communities) and
suggested that a single definition may not capture all
groups likely to be under-represented.
Targeted scoping review of definitions for under-served
groups
A total of 58 full-text papers were eligible for review; a
description of all considered full-text papers is given in
Additional file 3. The majority (39/58) of papers studied
patients from the USA; 15 studies reported data from
globally distributed sources, often as part of systematic
or narrative reviews, and 4 studies reported data col-
lected from other countries. Types of under-represented
groups were similar in both cancer and non-cancer
literature, including broad groupings such as children,
older people, patients with multimorbidity, pregnant
women, ethnic minorities, the socioeconomically disad-
vantaged, people outside usual primary and secondary
healthcare settings and those with cognitive impairment.
The majority of the literature (31/58 studies) engaged
with a specific subgroup or population. Common the-
matic barriers identified in the literature that may lead
to under-representation include the presence of comor-
bidities, logistical barriers (including lack of transport,
remoteness of study sites from usual abode), information
not available in a language or form to allow easy com-
prehension, low trust or low engagement with healthcare
services and low awareness of clinical trial opportunities.
Reviews retrieved as part of the literature review reinforced
that under-representation of some groups (especially
women and ethnic minority groups) was still prevalent in
major disease areas such as cancer and cardiovascular dis-
ease trials, and also highlighted that many studies do not
even collect or report information to enable a judgement
on whether a group was under-represented in a particular
trial [9, 10].
Surveys
Seventy people completed the participant stakeholder
on-line survey. Respondents were not asked directly for
details regarding which under-served group they were a
member of but reported the route by which they had re-
ceived the invitation to participate. Participants received
the invitation via VOICE in 11 (16%) of cases, via their
role as Patient Research Ambassadors in 8 (11%) of
cases, from other sources within the NIHR Clinical Re-
search Network in 11 (16%) cases, via medical charities
in 6 (9%) of cases and from other sources in 19 (27%) of
cases. The remaining 15 (21%) did not respond to this
question. Forty-one respondents (59%) agreed that itwas difficult to be clear about what under-representation
means.
One hundred and one professionals completed the
survey. Thirteen (13%) were research nurses, and 13
(13%) were academic researchers. Fourteen (14%) were
staff from clinical trial units, including unit directors.
Twelve (12%) were research managers, nine (9%) were
CRN Specialty leads and a further 11 (11%) held other
CRN roles. Smaller numbers of contributors represented
industry (6 [6%]), the NHS (6 [6%]), PPI engagement
professionals (5 [5%]) and charities (2 [2%]), with 10
(10%) not responding to this question. Fifty-six respon-
dents agreed that a universal definition of under-repre-
sentation could not be given, 14 disagreed with the
statement and 17 stated that they did not know.
Table 1 shows the under-served groups that were identi-
fied by the stakeholder, professional and patient representa-
tives. A small number of respondents also suggested
groups that they judged not to be under-served: these were
children, older people, people living with frailty, people with
multiple conditions, women and socioeconomically disad-
vantaged groups. These groups overlap with groups judged
by others to be under-served, but no respondent named a
group as both under-served and not under-served.
Twenty respondents went on to provide their own
definition of under-representation. These definitions
were broadly grouped into three areas: (1) inclusion, (2)
epidemiology and (3) miscellaneous. Inclusion includes
all submissions that considered under-representation to
be defined by poor access to trials in certain population
groups. Epidemiology is those that consider under-
representation to be defined in epidemiological terms,
i.e. the trial participant population demographics failing
to mirror the demographics of the target population in
the ‘real world’. Miscellaneous includes those submis-
sions that could not be grouped (n = 7). Some of these
submissions did attempt to provide definitions of under-
representation, for example ‘People who do not usually
feature in the demographics of those recruited to clinical
trials’ (participant ID 10210064831). However, many
were commentary on the issue rather than definition, for
example ‘I have found - for example - none of the stud-
ies I have been involved with have been gender specific,
however, nearly always I screen and recruit more males
than females…’ (participant ID 10210238642). Table 2
summarises the barriers to trial inclusion identified by
the participant and professional surveys.
Output from second stakeholder meeting
The consensus meetings considered the information
from the literature review and surveys, adding to and re-
fining the list of examples of innovative practice that had
emerged from the survey. A consensus emerged that
‘under-served groups’ be used as the preferred term for
Table 1 Under-served groups identified from stakeholder
groups and surveys
Groups by demographic factors
Age extremes (e.g. under 18 and over 75)
Women of childbearing age
Black, Asian and Ethnic Minorities (BAME)
Male or female sex (depending on trial context)
LGBTQ/sexual orientation
Educational disadvantage
Groups by social and economic factors
In full-time employment
Unemployed/low income
Military veterans
People in alternative residential circumstancesa
People living in remote areas
Religious minorities
Carers
People not fluent in the majority language
People who do not attend regular medical appointments
People in multiple excluded categories
Socially marginalised people
Stigmatised populations
Looked after children
Groups by health status
Mental health conditions
People who lack the capacity to consent for themselves
Cognitive impairment
Learning disability
People with addictions
Pregnant women
People with multiple health conditions
Physical disabilities
Visually/hearing impaired
Too severely ill
Smokers
People living with obesity
Groups by disease-specific factors
Rare diseases and genetic disease subtypes
People in cancer trials with brain metastases
aThis category includes migrants, asylum seekers, prison populations, care
homes, traveller communities and homeless
Table 2 Barriers to inclusion
Barrier
Barriers relating to physical disability
Difficulties in consenting for another person
Feeling unqualified to take part (e.g. due to lack of education)
Lack of available trials/poor trial promotion
Lack of effective incentives for participation
Lack of interest in research
Lack of trust in trials
Negative attitudes to the concept of research
Negative financial impact
Potential participants refusing to accept their health condition
Poor consent procedures
Requirement for additional carer time to aid participant
Participant risk perception
Specific cultural barriers
Specific health fears (e.g. hospitals, needles)
Treatment centres not set up for research
Trials asking too much for participation
Unwilling to receive placebo
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avoid any attachment of blame for low levels of partici-
pation. It also ensured that the onus was firmly on the
research infrastructure and process to find ways to
provide an appropriate solution or service to prospective
research participants. Consensus was also reached that asingle universal definition for what constitutes an under-
served group was unlikely to be possible. There was
consensus that the definition is context-specific, but that
important elements include a mismatch between a
population affected by a condition and those enrolled in
studies; a lack of opportunity to participate due to study
design, logistical or cultural barriers; and a lack of suit-
ability of the intervention under study for a particular
group due to physiological, logistical or cultural factors.
Stakeholders listed their priorities for the work of the
group over the coming year to achieve the vision of ‘bet-
ter healthcare through more inclusive research’; the top
six priorities (in priority order) were:
1. Embed research within healthcare to improve
access
2. Need for a set of information resources and training
to support research teams, community
representatives and clinical/support staff/other key
stakeholders (including funders) in building capacity
and sustainable engagement to enable development
and delivery of research to the under-served
3. Funders to engage with and enable provision for
under-served groups, making trials appropriate to
the real-world group(s) targeted by the intervention
4. More patient-centredness throughout the research
process (for example information and consent,
dissemination); Community Partnered Participatory
Research (CPPR)
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are and why they matter—TV series, features, etc.
6. Baseline measurement to assess the current
situation and to help document improvement
Following the second consensus meeting, the steering
group reviewed all the project outputs and proposed a
set of overarching goals together with an initial list of
potential solutions and actions to achieve these goals.
The project was branded as ‘Innovations in Clinical Trial
Design and Delivery for the under-served’ (INCLUDE)
at this point.Output from the third stakeholder meeting
At the final meeting, the set of goals identified from the
work to date was presented to the stakeholder group.
The group generated further potential solutions and
high-level actions, and the steering group then generated
four key objectives of equal importance for future work:
A) Develop Community Partnered Participatory
Research (CPPR) building long-term relationships
with under-served groups and opportunities for
participationFig. 2 Workstreams to take forward in the programmeB) Develop training resources to design and deliver
trials for under-served for all stakeholders involved,
and tailor resources to the needs of specific groups
C) Develop infrastructure and systems to reach,
engage, recruit and retain under-served groups
D) Work with funders, regulators and other
stakeholders to ensure barriers in funding,
regulations and policies are removed to enable
inclusion of under-served groups
To address these objectives, the steering group identi-
fied four overlapping workstreams to take forward; each
workstream addresses multiple objectives. These are
shown in Fig. 2.Final strategic roadmap
The steering group combined all the outputs from the
project surveys, scoping review and stakeholder meetings
to produce a strategic roadmap for initiatives to improve
access to clinical research for under-served groups. The
roadmap is intended to guide groups wishing to focus
on the needs of specific under-served groups, and to
help researchers work with under-represented groups; it
does not aim to provide solutions (which will be specific
Fig. 3 Roadmap to guide initiatives to improve inclusion of underserved groups into clinical research. Processes are embedded in the context of
ethics and regulatory requirements and evolving digital technology developments. Boxes represent key points for considering inclusion of
underserved groups over the lifecourse of the study
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both future research and for initiatives to address
barriers to participation that have been identified during
the project. The final roadmap is shown in Fig. 3.
Discussion and future directions
The INCLUDE project has identified a preferred label
(‘under-served groups’) to support conversations around
improving the inclusion of under-served groups in
clinical research, has identified a range of example
under-served groups, has identified common barriers to
participation and has produced a strategic roadmap and
plan to inform future work in this field. The recognition
that clinical research often fails to engage with groups
that it needs to is not new, and several papers included
in our literature review reinforce that key groups such as
older people, ethnic minorities and women are still
under-represented in clinical studies. Worse still, data
are lacking in many study reports on key study charac-
teristics that are needed to understand if under-served
groups are included in clinical research. Despite the rec-
ognition that a problem exists, attempts to address the
problem in a systemic way have been lacking to date.
Most studies on barriers to recruitment originate from
the USA, and many are specific to cancer research [11,
12]. Examples exist of research exploring barriers and so-
lutions to participation in other areas, for instance older
people, those from ethnic minorities and those in acute or
critical care [13–17]. Different areas of research have
different barriers in engagement to overcome; hence, a
tailored approach is required. Nevertheless, there are likely
to be common, generic issues (such as funding and regula-
tory disincentives) that could be tackled by generic action,
and a framework for future action such as we propose
here is also likely to reduce duplication of effort,redundancy and hence research waste in identifying good
practice and approaches to the problem.
The barriers identified by our surveys accorded well
with those identified in our literature search and encom-
passed those initially suggested by our stakeholder group.
Previous work has identified themes of trial awareness,
opportunity, acceptance of enrolment, perceptions of the
research process, logistical barriers and whether trial
processes were able to fit into participants’ existing lives
[18, 19]. These issues group in a similar way to the bar-
riers we identified. Although we did not find initiatives
with exactly the same aim and scope as our work, there
are others that either overlap or are complementary. Of
particular note are initiatives to improve recruitment to
and retention in trials [20] and ways to improve trial
design methods [21]. Our work is well placed to comple-
ment and enhance these and other initiatives.Strengths
The work we describe was successful in obtaining con-
sensus on strategic guidance for future work in this area
and had the strength of involving a wide range of stake-
holders including those from under-served groups. The
use of a range of methods, drawing on expert opinion,
published literature and focussed surveys, provided the
ability to triangulate data from multiple sources,
strengthening the final set of objectives and the final
roadmap. Although much of the existing literature
surveyed was conducted in the context of clinical trials,
the work of the INCLUDE project stakeholder and steer-
ing group kept a perspective that encompassed all types
of clinical research, and the outputs from the project
should therefore be of relevance to a broad range of
clinical research, not just trials.
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The work we describe was conducted as a focussed,
time-limited project. It was not conceived or executed as
a pure scientific investigation, and thus, some compro-
mises were necessary in terms of depth and extent of
enquiry. We did not attempt to apply a full systematic
review methodology to our literature review, but instead
used a focussed scoping review method which better fit-
ted the needs of the project. Although we were success-
ful in obtaining a wide range of stakeholder views, we
acknowledge that in terms of numbers, representation
was stronger from the academic and research delivery
communities than from other areas such as commercial
or charity representatives. Not all barriers identified by
respondents and participants will apply to all groups or
all trials; barriers are context-dependent, and not all bar-
riers will be surmountable for a particular trial. A better
understanding of what respondents meant for some bar-
riers is needed; some responses were ambiguous or
would benefit from clarification. This should be a focus
for future in-depth qualitative enquiry.Future directions
Several key strands of activity within the UK research com-
munity will flow from the work reported here, using the
roadmap as a strategic guide to address the needs of
under-served groups in research. Through its next phase,
the INCLUDE project will focus on the four workstreams
shown above. The project will engage with funders and
regulators to ensure that the issue of representation of
under-served groups is taken into account in funding deci-
sions, regulatory approvals, policies and making sufficient
resources available. In addition, the project will partner
with others already working in this field, signposting re-
search and delivery teams to existing resources [16], collab-
orating with others to develop infrastructure and training
solutions tailored to the needs of distinct under-served
groups, and developing the tools that research teams re-
quire to engage with under-served groups and design clin-
ical studies that effectively recruit and retain people (which
current studies fail to achieve). Although our focus remains
on improving UK research delivery, the generic nature of
the barriers we identified means that our roadmap is
equally applicable to international initiatives to improve re-
search delivery, including initiatives in lower and middle-
income countries. We hope that the INCLUDE framework
will provide a structure and a catalyst to improve study de-
sign and delivery, improve intervention design and get
more people from under-served groups into clinical re-
search, with a consequent improvement in the quality,
credibility and applicability of research data and hence bet-
ter healthcare delivery for a wide range of currently under-
served groups.Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-04613-7.
Additional file 1. Sample search strategy for targeted scoping review –
Medline database search.
Additional file 2. Content of survey questions for stakeholder groups.
Additional file 3. Description of included studies from targeted scoping
review.
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